Fractyl Health is a leading metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including T2D and obesity. Fractyl's Revita® and Rejuva® platform candidates are catheter-based treatments designed to target root causes of metabolic diseases and to transform metabolic disease treatment from chronic management to potentially preventing and reversing metabolic disease. Fractyl commenced trading on NASDAQ in February 2024 under the ticker symbol GUTS.